| Identification | Back Directory | [Name]
9H-Purine-2,6-diamine, N2-[4-(tetrahydro-4H-1,4-selenazin-4-yl)phenyl]-N6-[(3S)-tetrahydroselenophene-3-yl]- | [CAS]
2403650-93-9 | [Synonyms]
9H-Purine-2,6-diamine, N2-[4-(tetrahydro-4H-1,4-selenazin-4-yl)phenyl]-N6-[(3S)-tetrahydroselenophene-3-yl]- | [Molecular Formula]
C19H23N7Se2 | [MOL File]
2403650-93-9.mol | [Molecular Weight]
507.35 |
| Hazard Information | Back Directory | [Uses]
SLLN-15 is an oral active, selective and potent enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC)[1]. | [in vivo]
SLLN-15 (30mg/kg, PO, 3 times a week) not only inhibits the growth of TNBC in animal model, but also TNBC cell progression to metastases[1].
Overall, oral SLLN-15 reveals a potent anticancer and anti-metastatic activity in mice bearing TNBC[1]. | Animal Model: | BALB/c mice or SCID mice transplanted with mouse mammary carcinoma 4T1 cells and human breast adenocarcinoma MDA-MB-231 cells (1 X 106 cells/ each mouse)[1] | | Dosage: | 30mg/kg. | | Administration: | PO, 3 times a week for 40 days. | | Result: | Tumor allografts grew at a slower rate compared to control groups.
Significant inhibition of the number of lung metastases as visualized.
|
| [References]
[1] Chang CH, et al. A novel orally available seleno-purine molecule suppresses triple-negative breast cancer cell proliferation and progression to metastasis by inducing cytostatic autophagy. Autophagy. 2019 Mar 1:1-15. DOI:10.1080/15548627.2019.1582951 |
|
|